Skip to content
TheChatArchiveThe Chat Archive
o1-mini-2024-09-12· OpenAIAi2 WildChat-4.8M (AI2)

Here is some background information for a PhD proposal titled "Developing and evaluating…

  1. User

    Here is some background information for a PhD proposal titled "Developing and evaluating novel methods to improve the accuracy and portability of PRS for specific underrepresented populations," drawing on the provided sources: Background Information: Polygenic Risk Scores and the Need for Improved Generalizability Polygenic risk scores (PRS) are used to predict an individual’s susceptibility to diseases and other complex traits by aggregating the effects of many genetic variants across the genome. They have shown promise for advancing precision medicine, but a major limitation is their limited portability across diverse populations. Historical Development of PRS Early PRS methods often involved calculating scores based on a subset of relatively independent SNPs exceeding a specific GWAS association P value threshold. This method was used in some of the first studies that showed statistically significant PRS prediction.

    this is reference and citation method of chatbot, please generate a prompt that reasening and reference of this chatbot like a paper

  2. Assistant

    Background

    Polygenic Risk Scores and the Need for Improved Generalizability

    Polygenic Risk Scores (PRS) have become increasingly instrumental in predicting an individual’s susceptibility to various diseases and complex traits by aggregating the effects of numerous genetic variants across the genome (Smith et al., 2020). This approach leverages Genome-Wide Association Studies (GWAS) data to identify single nucleotide polymorphisms (SNPs) that contribute to the heritability of specific conditions (Johnson & Wang, 2019). PRS hold significant promise for advancing precision medicine by enabling personalized prevention and treatment strategies tailored to an individual's genetic profile (Lee et al., 2021). However, a substantial limitation of current PRS methodologies is their limited portability across diverse populations. Most PRS models are derived from GWAS conducted predominantly in European populations, which leads to reduced accuracy and generalizability when applied to underrepresented groups (Kim et al., 2022). This disparity underscores the urgent need for developing and evaluating novel methods to enhance the accuracy and portability of PRS for specific underrepresented populations.

    Historical Development of PRS

    The foundational development of PRS involved calculating scores based on a selected subset of relatively independent SNPs that exceeded a predetermined GWAS association p-value threshold (Doe & Smith, 2018). This initial methodology facilitated the identification of genetic variants with significant associations to particular traits or diseases, thereby enabling the construction of predictive models (Brown et al., 2020). Early studies utilizing this approach demonstrated statistically significant PRS predictions, validating the concept of polygenic risk prediction (Garcia et al., 2019). However, these methods primarily relied on linkage disequilibrium (LD) pruning and p-value thresholding, which may not capture the complex genetic architecture underlying many traits, especially in diverse populations (Miller & Thompson, 2021). Consequently, while early PRS models provided a proof of concept, their applicability remains constrained by population-specific genetic variations and the lack of representation in discovery datasets (Nguyen et al., 2023). Addressing these challenges is critical for the equitable implementation of PRS in precision medicine and for mitigating health disparities across different demographic groups.

    References

    • Brown, A. B., et al. (2020). Development of polygenic risk scores for complex traits. Journal of Genetic Epidemiology, 45(3), 234-245.
    • Doe, J., & Smith, L. (2018). Early methodologies in polygenic risk scoring. Genetics Research, 50(2), 112-120.
    • Garcia, M. T., et al. (2019). Validation of polygenic risk scores in diverse populations. Nature Genetics, 51(4), 567-574.
    • Johnson, K., & Wang, Y. (2019). Advancements in precision medicine through polygenic risk scores. Precision Medicine Journal, 7(1), 34- forty-two.
    • Kim, S., et al. (2022). Population disparities in polygenic risk score portability. American Journal of Human Genetics, 110(5), 789-799.
    • Lee, H., et al. (2021). Enhancing the utility of polygenic risk scores in clinical settings. Clinical Genetics, 99(6), 987-995.
    • Miller, R., & Thompson, J. (2021). Challenges in polygenic risk prediction for diverse populations. Genetic Medicine, 23(7), 1504-1513.
    • Nguyen, P., et al. (2023). Towards inclusive polygenic risk scores: Methodological innovations and applications. Nature Communications, 14(1), 1023.
    • Smith, J., et al. (2020). Polygenic risk scores: Current status and future directions. Annual Review of Genomics and Human Genetics, 21, 341-362.

    Note: The references provided above are illustrative and should be replaced with actual sources relevant to your research.